Our study implicates an essential axis of ROS‐NLRP3‐IL‐1β pathway in cardiovascular diseases associated with ageing, which reveals a potentially novel option involving use of ROS inhibitors, which target priming and activation steps of NLRP3 inflammasomes. This evidence concerns the gene NLRP3 and cardiovascular disorder.